| Source: |
| Type: |
| Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin. EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin). EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis. |
| 1094- | ACNs, | Anthocyanidins inhibit epithelial-mesenchymal transition through a TGF-β/Smad2 signaling pathway in glioblastoma cells: Anthocyanidins inhibit TGF-β-mediated EMT. |
| - | in-vitro, | GBM, | U87MG |
| 1097- | AG, | Astragalus Inhibits Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelial Cells by Down-Regulating β-Catenin |
| - | in-vitro, | Nor, | HMrSV5 | - | in-vivo, | NA, | NA |
| 5444- | AG, | A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Astragali Radix: Implications for Astragali Radix as a Personalized Medicine |
| - | Review, | Var, | NA |
| 5431- | AG, | Advances in research on the anti-tumor mechanism of Astragalus polysaccharides |
| - | Review, | Var, | NA |
| 5433- | AG, | Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in m6A-mediated OSCC treatment |
| - | vitro+vivo, | OS, | NA |
| 5434- | AG, | Recent Advances in the Mechanisms and Applications of Astragalus Polysaccharides in Liver Cancer Treatment: An Overview |
| - | Review, | Liver, | NA |
| 5438- | AG, | Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in mA-mediated OSCC treatment |
| - | vitro+vivo, | NA, | NA |
| 2662- | AL, | Allicin inhibits tubular epithelial-myofibroblast transdifferentiation under high glucose conditions in vitro |
| - | in-vitro, | Nor, | HK-2 |
| 284- | ALA, | Lipoic acid a multi-level molecular inhibitor of tumorigenesis |
| - | Review, | Var, | NA |
| 278- | ALA, | The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment |
| - | Review, | NA, | NA |
| 276- | ALA, | Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B |
| 1124- | ALA, | Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells |
| - | in-vitro, | Thyroid, | BCPAP | - | in-vitro, | Thyroid, | HTH-83 | - | in-vitro, | Thyroid, | CAL-62 | - | in-vitro, | Thyroid, | FTC-133 | - | in-vivo, | NA, | NA |
| 1548- | Api, | A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms |
| - | Review, | Colon, | NA |
| 1547- | Api, | Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading |
| - | Review, | NA, | NA |
| 1095- | Api, | Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway |
| - | Analysis, | Colon, | NA |
| 210- | Api, | Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer |
| - | in-vitro, | Pca, | DU145 |
| 244- | Api, | Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma |
| - | in-vivo, | Melanoma, | B16-F10 | - | in-vivo, | Melanoma, | A375 | - | in-vivo, | Melanoma, | G361 |
| 3382- | ART/DHA, | Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge? |
| - | Review, | Var, | NA |
| 3383- | ART/DHA, | Dihydroartemisinin: A Potential Natural Anticancer Drug |
| - | Review, | Var, | NA |
| 1099- | ART/DHA, | Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway |
| - | in-vitro, | NA, | NA |
| 5415- | ASA, | The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review |
| - | Review, | Var, | NA |
| 5398- | Ash, | Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90/HIF-1α/EMT axis |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 3172- | Ash, | Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 3156- | Ash, | Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug |
| - | Review, | Var, | NA |
| 3160- | Ash, | Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal |
| - | Review, | Var, | NA |
| 3166- | Ash, | Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives |
| - | Review, | Var, | NA |
| 1358- | Ash, | Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms |
| - | Review, | Var, | NA |
| 1181- | Ash, | Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 5172- | Ash, | Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells |
| 4814- | ASTX, | Chemopreventive and therapeutic efficacy of astaxanthin against cancer: A comprehensive review |
| - | Review, | Var, | NA |
| 4812- | ASTX, | Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a |
| - | in-vitro, | CRC, | HCT116 |
| 5452- | ATV, | Mevalonate pathway in pancreatic ductal adenocarcinoma: mechanisms driving metabolic and cellular plasticity |
| - | Review, | Var, | NA |
| 5447- | ATV, | The Mevalonate Pathway, a Metabolic Target in Cancer Therapy |
| - | Review, | Var, | NA |
| 5446- | ATV, | Targeting the Mevalonate Pathway in Cancer |
| - | Review, | Var, | NA |
| 999- | Ba, | Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer |
| - | in-vitro, | Lung, | H460 |
| 5502- | Ba, | An overview of pharmacological activities of baicalin and its aglycone baicalein: New insights into molecular mechanisms and signaling pathways |
| - | Review, | Var, | NA |
| 2473- | BA, | Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B | - | in-vitro, | Lung, | H460 |
| 2630- | Ba, | Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice |
| - | in-vivo, | Nor, | NA |
| 2290- | Ba, | Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer |
| - | Review, | GI, | NA |
| 5551- | BBM, | Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis |
| - | vitro+vivo, | Bladder, | NA |
| 1392- | BBR, | Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | MKN45 |
| 2678- | BBR, | Berberine as a Potential Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 2686- | BBR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Nor, | NA |
| 1102- | BBR, | Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells |
| - | in-vitro, | Melanoma, | B16-BL6 |
| 1031- | BCA, | Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer |
| - | vitro+vivo, | CRC, | HCT116 | - | vitro+vivo, | CRC, | SW-620 |
| 2729- | BetA, | Betulinic acid in the treatment of tumour diseases: Application and research progress |
| - | Review, | Var, | NA |
| 2731- | BetA, | Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives |
| - | Review, | GBM, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 2738- | BetA, | Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
| 2741- | BetA, | Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress |
| - | in-vitro, | GC, | SNU16 | - | in-vitro, | GC, | NCI-N87 | - | in-vivo, | NA, | NA |
| 2743- | BetA, | Betulinic acid and the pharmacological effects of tumor suppression |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:96 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid